Incidence of nausea and vomiting during radiotherapy

Incidence of radiotherapy induced nausea and vomiting (RINV) - Incidence of radiotherapy induced nausea and vomiting (RINV)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046427

Enrollment

Registered

2021-12-21

Start date

2020-03-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients receiving radiotherapy for malignancy either as definitive, palliative, or post-operative adjuvant therapy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients providing written consent to participate in study 2) Aged over 20 years old at time of participation 3) Treated with photon radiotherapy at dose of over 20 Grays / 4 Fractions

Exclusion criteria

Exclusion criteria: 1) Patients receiving concomitant chemotherapy 2) Patients with stoma 3) Patients presenting with, or have a history of ileus 4) Judged by the investigator as unfit for inclusion in study

Design outcomes

Primary

Measure	Time frame
To investigate the incidence of RINV according to irradiated site and observe the efficacy of antiemetic treatment by evaluating the proportion of emesis-free days and nausea-free days.	—

Secondary

Measure	Time frame
Time to first incidence of nausea or vomiting, frequency of vomiting, severity of nausea including impact on eating habits and weight loss.	—

Countries

Japan

Contacts

Public ContactKayo Yoshida

Keio University School of Medicine Department of Radiation Oncology

kayoyoshida@rad.med.keio.ac.jp03-3353-1211

Outcome results